This stock is no longer traded. It was delisted on July 21, 2026. Prices stop on that date; discussion is still counted.
Generated by AI
XOMA Corporation 8.375% Perpetual Preferred Stock is a type of preferred equity that offers investors a fixed dividend yield of 8.375%. This financial instrument is issued by XOMA Corporation, a biotechnology company specializing in the discovery and development of novel antibody therapeutics. The perpetual nature of this preferred stock indicates that it does not have a maturity date, allowing it to exist indefinitely, which is advantageous for investors seeking regular income streams over an extended period. The primary function of this asset is to provide a stable and predictable income, appealing to institutions or individuals seeking lower volatility compared to common stock. Additionally, preferred stockholders typically have precedence over common shareholders regarding dividend payments and asset distribution in the event of liquidation, although they generally lack voting rights. In the financial market, this perpetual preferred stock plays a vital role in balancing portfolios with fixed-income characteristics, often drawing interest from those who prioritize income over capital appreciation in industries related to biotechnology and pharmaceuticals.
Website2200 Powell Street
EmeryVille, CA, 94608
United States
The latest articles about XOMAO.
On August 6, Ligand Pharmaceuticals (NASDAQ:LGND) reported second-quarter 2026 results showing royalty revenue up 32% year over year, just weeks after the company closed its acquisition of XOMA Royalty. Total revenue reached $63.7 million for the quarter, up from $47.6 million a year earlier, and Ligand raised the low end of its full-year adjusted earnings […]
UTRECHT, The Netherlands and PHILADELPHIA, Nov. 10, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (“LAVA”) (NASDAQ: LVTX) today announced a reminder to...
Ligand Pharmaceuticals (NASDAQ:LGND) outlined its royalty-focused growth strategy, recent XOMA acquisition and portfolio catalysts during a company presentation, highlighting a larger commercial-stage asset base and planned investment capacity. Chief Financial Officer Tavo Espinoza said Ligand has
Summary of Nov 7's posts. Generated by AI.
No summary yet.
No summary yet.
No summary yet.
No summary yet.
Investors talking about XOMAO also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.